Australia secured more than 84 million doses of potential COVID-19 vaccines

By: Miguel A. Rodriguez

09:45, 14 September 2020

AstraZeneca scored another deal

As the pharmaceutical companies are getting close to releasing a viable #COVID-19 vaccine, countries worldwide are starting to secure millions of doses. The latest country to be part of this movement is Australia.

Australia announced that it would receive 3.8 million doses of the vaccine developed by AstraZeneca during the first two months of 2021. Currently, the vaccine is in Phase III of clinical trials in the US, Brazil, South Africa, and the UK. It hasn't revealed significant concerns, but it generated strong immune responses. Under the contract, the Australian government could purchase up to 30 million additional doses.  

But the government’s mission doesn’t stop here. It will also purchase doses of the #vaccine developed by the University of Queensland (UQ). Unlike the ones from AstraZeneca, the UQ ones will be available mid-2021. The UQ is undergoing pre-clinical testing on 120 adults, following promising results on animal trials. From the University, the government will buy 51 million doses.  

According to people familiar with the matter, vulnerable people and healthcare workers will be the first in line to receive the vaccine. However, things are still a topic of discussion among health officials.

Under the agreements, as mentioned before, the government has the possibility of purchasing additional doses. Also, it can donate or sell the remaining vaccines to other countries or international organizations. From nearly 85 million doses, if both vaccines are proven effective, Australia will have around 30 million doses to spare.

As far as both vaccines are concerned, they could require two doses per patient – an initial dose and a booster. The overall deal for both vaccines is of 1.24 billion.

Following today’s announcement, AstraZeneca stock price is trading 3.50% higher. Australia200 ended the session at +0.33%. 

Read more about other pharma companies and their vaccines here!

Sources: investing.com, theguardian.com, yahoo.com


Share this article

This information prepared by capex.com/za is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of capex.com/zaJME Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.